|
"buti m"的相關文件
顯示項目 11-14 / 14 (共1頁)
1
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2018-09-10T15:24:48Z |
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
|
Buti, M.;Flisiak, R.;Kao, J.-H.;Chuang, W.-L.;Streinu-Cercel, A.;Tabak, F.;Calistru, P.;Goeser, T.;Rasenack, J.;Horban, A.;Davis, G.L.;Alberti, A.;Mazzella, G.;Pol, S.;Orsenigo, R.;Brass, C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2018-09-10T08:44:43Z |
Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease
|
Keating, G.M.; Buti, M.; Gadano, A. ;Kao, J.-H. ;Lee, C.-M.; Peng, C.-Y.; Schiff, E.R.; Tanwandee, T.; JIA-HORNG KAO |
| 國立臺灣大學 |
2013 |
ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)
|
Buti, M.; Flisiak, R.; Rasenack, J.; Davis, G.; Alberti, A.; Goeser, T.; Stanciu, C.; Chuang, W. -L.; Tabak, F.; Kao, J. -H.; Streinu-Cercel, A.; Hofstetter, G.; Wang, J.; Avila, C.; Orsenigo, R.; 高嘉宏 |
| 國立臺灣大學 |
2012 |
ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR
|
Alberti, A.; Chuang, W. -L.; Flisiak, R.; Mazzella, G.; Horban, A.; Goeser, T.; Calistru, P.; Buti, M.; Davis, G.; Gong, Y.; Avila, C.; Kao, J. -H.; 高嘉宏 |
顯示項目 11-14 / 14 (共1頁)
1
每頁顯示[10|25|50]項目
|
